Dr. Reddy’s Laboratories Ltd. on January 24 announced the launch of its Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s is committed to providing affordable and innovative medicines for healthier lives. To that end, Dr. Reddy’s neither condones nor supports the off-label use or misuse of its drugs. ''In the strongest possible terms, Dr. Reddy’s objects to the use of any of its products to facilitate or otherwise aid lethal injections. Consistent with this position, Dr. Reddy’s uses distribution controls to market Propofol Injectable Emulsion, USP.

Dr. Reddy’s will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. We require the same commitment from our wholesalers and distributors,''the company said. The Diprivan brand and generic had U.S. sales of approximately $310 million MAT for the most recent twelve months ending in November 2018 according to IMS Health. The company's Propofol Injectable Emulsion, USP is available in 10 mg/mL vials for single patient use only.